Skip to main content

FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection, Sanofi Aventis Australia Pty Ltd, CON-262

Product name
FluQuadri Inactivated Quadrivalent Influenza Vaccine (Split Virion), Influenza virus haemagglutinin 60 mcg, 0.5 mL suspension for injection
Sponsor name
Sanofi Aventis Australia Pty Ltd
Batches
UI942AC
Consent start
Consent no.
CON-262
Standard
European Pharmacopeia (01/2008:0158) test for Bacterial Endotoxins (2.6.14) and the assay of Haemagglutinin Antigen by an immunodiffusion test (2.7.1) and Therapeutic Goods Order No. 91 '“ Standard for labels of prescription and related medicines (TGO 91).
Non-compliance with standard
1. European Pharmacopeia (01/2008#58;0158) the test for Bacterial Endotoxins (2.6.14) and the assay of Haemagglutinin Antigen by an immunodiffusion test (2.7.1), are performed on the Final Bulk Product only and not performed on the Final Lot. 2. Therapeutic Goods Order No. 91 '“ Standard for labels of prescription and related medicines (TGO91)' The batch is packaged in the Standard Export labelling (in Spanish and English), which does not conform with the requirements of the TGO 91 on the following#58; Paragraph 8(1)(d) the name of the dosage form (missing on carton) Paragraph 8(1)(i) the name and contact details of the sponsor (missing on carton) Paragraph 8(1)(j)(iv)(A) indicating that the medicine contains the substance expressed using the Name stated in Column 4 of Schedule 1 (statement regarding manufactured in eggs missing on carton) Paragraph 9(1)(b) the name(s) of all active ingredients in the medicine (missing on syringe) Paragraph 9(1)(c) the quantity or proportion of all active ingredients in the medicine (missing on syringe) Paragraph 9(3) the name of the medicine and the name of active ingredients on the main label (they are placed separately as the same texts in Spanish are placed before English texts) Paragraph 10(5)(c) the name of the medicine is displayed in a text size of not less than 1.5 millimetres (the trade name quot;FluQuadriquot; is less than 1.5 mm on syringe) Paragraph 11(1)(a) use of appropriate metric units (the abbreviation quot;mcgquot; is used rather than quot;microgramquot; in full on carton) Subsection 11(5) permitted statements of storage temperature conditions (quot;Store between +2oC to +8oC. Do not freezequot; is used rather than quot;Store at 2oC to 8oCquot; (Refrigerate. Do not freeze) on carton).
Conditions imposed
    1. This consent applies only to the FluQuadri batch UI942AC.     2. A 'Dear Healthcare Professional' letter identical to that provided to the TGA on 21 May 2018 will be supplied with the affected batch.     3. Non'compliance with the European Pharmacopoeia is limited to the tests detailed in the application submitted to the TGA on 18 May 2018.     4. Non'compliance with the TGO 91 is limited to specifications detailed in the application form submitted to the TGA on 18 May 2018.      
Therapeutic product type
Prescription medicines

Help us improve the Therapeutic Goods Administration site